Novartis Investigative Site

Sherman, Texas 75092

0 studies enrolling now · 8 studies all time

What they study most

Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure, Reduced Ejection Fraction, Lymphoma, Non-Hodgkin, Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Scelrosis, Relapsing-remitting Multiple Sclerosis (RRMS)

Studies at this site

• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients — Completed
• Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. — Completed
• Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. — Completed
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed